
STALLERGENES GREER ANNOUNCES THE APPROVAL OF ACTAIR® IN AUSTRALIA

ACTAIR® IS THE FIRST SUBLINGUAL IMMUNOTHERAPY TABLET FOR THE TREATMENT OF HOUSE DUST MITE ALLERGY REGISTERED IN AUSTRALIA

DATE: April 5, 2016

London (United Kingdom) - Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that it has received the approval for ACTAIR®, its immunotherapy tablet for the treatment of house dust mite (HDM) induced respiratory allergy, from the Australian health authorities (TGA, Therapeutic Goods Administration).

“This approval marks an important milestone for us in Australia, where we first established our presence in 2008 and have since been the market leader in allergy immunotherapy. ACTAIR®, the first HDM tablet with a demonstrated post-treatment effect registered in Australia, will complement our comprehensive product portfolio in this country for the benefit of allergic patients”, stated Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer.

As the leading allergy immunotherapy company operating directly in the country, Stallergenes Greer has a comprehensive range of subcutaneous and sublingual immunotherapy products, including ORALAIR®, STALORAL®, and ALUSTAL® which continue to be available to meet the needs of Australian patients.

ABOUT HOUSE DUST MITE INDUCED ALLERGIC RHINITIS IN AUSTRALIA

Due to its climate and the concentration of the population in coastal cities, Australia is one of the industrialized countries most affected by allergies. Allergic rhinitis is one of the most common chronic respiratory conditions, affecting around 15% of Australians¹. The most common causative allergens include pollens, house dust mites, moulds, and insects, of which about 40-60% of the allergic rhinitis cases are due to house dust mite².

¹ Australian Institute of Health and Welfare: Authoritative information and statistics to promote better health and wellbeing- ISBN 978-1-74249-228-5; Cat. no. ACM 23; 50pp. <http://www.aihw.gov.au/>

² Sharp and Seeto, 2010, Smith et al., 2014

ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

This document (including information incorporated by reference in this document), oral statements made and other information published by the company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in our prospectus filed with the French Autorité des marchés financiers on September 3, 2015. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

Contacts:

Investor and analyst relations

Peter Bühler
 Chief Financial Officer
 Tel: +33 1 55 59 23 22
 Email: investorrelations@aresallergyco.com

Media relations

Lise Lemonnier
 Head of Global Communications
 Tel: + 33 1 55 59 20 96
 Email: llemonnier@stallergenes.com

Investor relations agency

FTI Consulting
 Arnaud de Cheffontaines
 Tel: +33 1 47 03 69 48
 Email:
arnaud.decheffontaines@fticonsulting.com

Media relations agency

Havas Worldwide Paris
 Jean-Baptiste Froville
 Tel: +33 1 58 47 95 39
 Email: jean-baptiste.froville@havasww.com